journal article·2013-03-26Open access

Skin Dendritic Cell Targeting via Microneedle Arrays Laden with Antigen-Encapsulated Poly-d,l-lactide-co-Glycolide Nanoparticles Induces Efficient Antitumor and Antiviral Immune Responses

Marija Zaric, Oksana Lyubomska, Olivier Touzelet, Candice Poux, Sharifah Al-Zahrani, Francois Fay, Leah Wallace, Dorothea Terhorst, Bernard Malissen, Sandrine Henri, Ultan F. Power, Christopher J. Scott, Ryan F. Donnelly, Adrien Kissenpfennig

ACS Nano· Volume 7· Issue 3

Abstract

The efficacious delivery of antigens to antigen-presenting cells (APCs), in particular, to dendritic cells (DCs), and their subsequent activation remains a significant challenge in the development of effective vaccines. This study highlights the potential of dissolving microneedle (MN) arrays laden with nanoencapsulated antigen to increase vaccine immunogenicity by targeting antigen specifically to contiguous DC networks within the skin. Following in situ uptake, skin-resident DCs were able to deliver antigen-encapsulated poly-d,l-lactide-co-glycolide (PGLA) nanoparticles to cutaneous draining lymph nodes where they subsequently induced significant expansion of antigen-specific T cells. Moreover, we show that antigen-encapsulated nanoparticle vaccination via microneedles generated robust antigen-specific cellular immune responses in mice. This approach provided complete protection in vivo against both the development of antigen-expressing B16 melanoma tumors and a murine model of para-influenza, through the activation of antigen-specific cytotoxic CD8(+) T cells that resulted in efficient clearance of tumors and virus, respectively. In addition, we show promising findings that nanoencapsulation facilitates antigen retention into skin layers and provides antigen stability in microneedles. Therefore, the use of biodegradable polymeric nanoparticles for selective targeting of antigen to skin DC subsets through dissolvable MNs provides a promising technology for improved vaccination efficacy, compliance, and coverage.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Advancements in Transdermal Drug Delivery · Immunotherapy and Immune Responses · Dermatology and Skin Diseases

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

The Centre for Infection and Immunity, School of Medicine, Dentistry and Biomedical Sciences, Queen’s University Belfast, University Road, Belfast BT9 7AE, United Kingdom

School of Pharmacy, Queen’s University Belfast, Lisburn Road, Belfast BT9 7BL, United Kingdom

Centre d’Immunologie de Marseille-Luminy (CIML), Aix Marseille Université, UM2, Marseille, France

INSERM U1104, Marseille, France

CNRS UMR7280, Marseille, France

References (54)

Show source-provided references
1. Steinman R. M. · Nat. Med. · 2007 · 13 · 115510.1038/nm1643 ↗
2. Steinman R. M. · Immunity · 2008 · 29 · 31910.1016/j.immuni.2008.08.001 ↗
3. Hegde N. R. · Drug Discovery Today · 2011 · 16 · 106110.1016/j.drudis.2011.07.004 ↗
4. Koutsonanos D. G. · PLoS One · 2009 · 4 · e477310.1371/journal.pone.0004773 ↗
5. Miller M. A. · Bull. World Health Org. · 1999 · 77 · 808
6. Prausnitz M. R. · Nat. Biotechnol. · 2008 · 26 · 126110.1038/nbt.1504 ↗
7. Combadiere B. · PLoS One · 2010 · 5 · e1081810.1371/journal.pone.0010818 ↗
8. Belshe R. B. · N. Engl. J. Med. · 2004 · 351 · 228610.1056/NEJMoa043555 ↗
9. Kenney R. T. · N. Engl. J. Med. · 2004 · 351 · 229510.1056/NEJMoa043540 ↗
10. Prausnitz M. R. · Adv. Drug Delivery Rev. · 2004 · 56 · 58110.1016/j.addr.2003.10.023 ↗
11. Al-Zahrani S. · Expert Opin. Drug Delivery · 2012 · 9 · 54110.1517/17425247.2012.676038 ↗
12. Kim Y. C. · Adv. Drug Delivery Rev. · 2012 · 64 · 154710.1016/j.addr.2012.04.005 ↗
13. Donnelly R. F. · Pharm. Res. · 2011 · 28 · 4110.1007/s11095-010-0169-8 ↗
14. Storni T. · Adv. Drug Delivery Rev. · 2005 · 57 · 33310.1016/j.addr.2004.09.008 ↗
15. Gutierro I. · Vaccine · 2002 · 21 · 6710.1016/S0264-410X(02)00435-8 ↗
16. Jaganathan K. S. · Vaccine · 2006 · 24 · 420110.1016/j.vaccine.2006.01.011 ↗
17. Mahapatro A. · J. Nanobiotechnol. · 2011 · 9 · 5510.1186/1477-3155-9-55 ↗
18. Panyam J. · Adv. Drug Delivery Rev. · 2003 · 55 · 32910.1016/S0169-409X(02)00228-4 ↗
19. Kumari A. · Colloids Surf., B · 2010 · 75 · 110.1016/j.colsurfb.2009.09.001 ↗
20. Hunter S. K. · Am. J. Obstet. Gynecol. · 2001 · 185 · 117410.1067/mob.2001.117658 ↗
21. Alonso M. J. · Vaccine · 1994 · 12 · 29910.1016/0264-410X(94)90092-2 ↗
22. Newman K. D. · J. Biomed. Mater. Res. · 2002 · 60 · 48010.1002/jbm.10019 ↗
23. Putney S. D. · Nat. Biotechnol. · 1998 · 16 · 15310.1038/nbt0298-153 ↗
24. Uchida T. · Biol. Pharm. Bull. · 1994 · 17 · 127210.1248/bpb.17.1272 ↗
25. Kumar A. · J. Controlled Release · 2012 · 163 · 23010.1016/j.jconrel.2012.08.011 ↗
26. Audran R. · Vaccine · 2003 · 21 · 125010.1016/S0264-410X(02)00521-2 ↗
27. De Geest B. G. · ACS Nano · 2012 · 6 · 213610.1021/nn205099c ↗
28. Burgdorf S. · Curr. Opin. Immunol. · 2008 · 20 · 8910.1016/j.coi.2007.12.002 ↗
29. Abdelghany S. M. · Int. J. Nanomed. · 2012 · 7 · 4053
30. Lutsiak M. E. · Pharm. Res. · 2002 · 19 · 148010.1023/A:1020452531828 ↗
31. Elamanchili P. · Vaccine · 2004 · 22 · 240610.1016/j.vaccine.2003.12.032 ↗
32. Vallhov H. · Nano Lett. · 2006 · 6 · 168210.1021/nl060860z ↗
33. Uto T. · J. Immunol. · 2007 · 178 · 297910.4049/jimmunol.178.5.2979 ↗
34. Donnelly R. F. · J. Controlled Release · 2010 · 147 · 33310.1016/j.jconrel.2010.08.008 ↗
35. del Pilar Martin M. · MBio · 2012 · 3 · e0001210.1128/mBio.00012-12 ↗
36. Henri S. · J. Exp. Med. · 2010 · 207 · 18910.1084/jem.20091964 ↗
37. Sullivan S. P. · Nat. Med. · 2010 · 16 · 91510.1038/nm.2182 ↗
38. Nishioka Y. · Adv. Drug Delivery Rev. · 2001 · 47 · 5510.1016/S0169-409X(00)00121-6 ↗
39. Reddy S. T. · J. Controlled Release · 2006 · 112 · 2610.1016/j.jconrel.2006.01.006 ↗
40. Torchilin V. P. · Adv. Drug Delivery Rev. · 2006 · 58 · 153210.1016/j.addr.2006.09.009 ↗
41. Vasir J. K. · Adv. Drug Delivery Rev. · 2007 · 59 · 71810.1016/j.addr.2007.06.003 ↗
42. Banchereau J. · Nature · 1998 · 392 · 24510.1038/32588 ↗
43. Gamvrellis A. · Immunol. Cell Biol. · 2004 · 82 · 50610.1111/j.0818-9641.2004.01271.x ↗
44. Waeckerle-Men Y. · Vaccine · 2006 · 24 · 184710.1016/j.vaccine.2005.10.032 ↗
45. Partidos C. D. · Vaccine · 2003 · 21 · 77610.1016/S0264-410X(02)00597-2 ↗
46. Stoitzner P. · J. Immunol. · 2008 · 180 · 199110.4049/jimmunol.180.3.1991 ↗
47. Seo N. · Proc. Natl. Acad. Sci. U.S.A. · 2000 · 97 · 37110.1073/pnas.97.1.371 ↗
48. Kissenpfennig A. · Immunity · 2005 · 22 · 64310.1016/j.immuni.2005.04.004 ↗
49. Hogquist K. A. · Cell · 1994 · 76 · 1710.1016/0092-8674(94)90169-4 ↗
50. Barnden M. J. · Immunol. Cell Biol. · 1998 · 76 · 3410.1046/j.1440-1711.1998.00709.x ↗
51. Tamoutounour S. · Eur. J. Immunol. · 2012 · 42 · 315010.1002/eji.201242847 ↗
52. Vremec D. · J. Immunol. · 2000 · 164 · 297810.4049/jimmunol.164.6.2978 ↗
53. Brown D. M. · Immunology · 2001 · 102 · 48610.1046/j.1365-2567.2001.01213.x ↗
54. Touzelet O. · Virus Res. · 2009 · 140 · 4010.1016/j.virusres.2008.10.019 ↗